| Name | N-Benzyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-7-quinazolinecarboxamide |
|---|---|
| Synonyms |
N-Benzyl-4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-7-quinazolinecarboxamide
7-Quinazolinecarboxamide, 1,2,3,4-tetrahydro-4-oxo-N-(phenylmethyl)-2-thioxo-3-[3-(trifluoromethyl)phenyl]- |
| Description | Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease[1][2]. |
|---|---|
| Related Catalog | |
| Target |
TDH[1] |
| In Vitro | Qc1 (10 μM; 2~24 hours; ES cells) shows that a substantial fraction of the total LC3 protein is in the LC3-I (cytoplasmic) form. After 16 h of TDH inhibition, most LC3 is converted to the LC3-II (lipid-modified) form, indicative of increased autophagic activity[2]. . Qc1 blocks the charging of tetrahydrofolate. Qc1 prevents threonine dehydrogenase from catabolizing threonine into acetyl-CoA and glycine[1][2]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C23H16F3N3O2S |
| Molecular Weight | 455.452 |
| Exact Mass | 455.091522 |
| PSA | 98.98000 |
| LogP | 4.34 |
| Index of Refraction | 1.682 |
| RIDADR | NONH for all modes of transport |
|---|